Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: A longitudinal study with positron emission tomography and flow-mediated dilation

Nuclear Medicine Communications

Volumn 31, Issue 10, 2010, Pages 874-880

  Kristoffersen, Ulrik Sloth ^a,b   Wiinberg, Niels ^c   Petersen, Claus Leth ^c   Gerstoft, Jan ^a   Gutte, Henrik ^a,b   Lebech, Anne Mette ^d   Kjaer, Andreas ^a,b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

endothelial function; flow mediated dilation; HIV; initiating antiretroviral therapy; positron emission tomography.

Indexed keywords

ABACAVIR; AMMONIA N 13; EFAVIRENZ; EMTRICITABINE; GLYCERYL TRINITRATE; LAMIVUDINE; RALTEGRAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COLD PRESSOR TEST; CONTROLLED STUDY; CORONARY ARTERY DILATATION; FLOW MEDIATED DILATION; HEART FUNCTION; HEART MUSCLE PERFUSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PULSE PRESSURE;

ADULT; AGED; AMMONIA; ANTI-HIV AGENTS; BRACHIAL ARTERY; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; VASOMOTOR SYSTEM; YOUNG ADULT;

EID: 77957344285     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32833d82e6     Document Type: Article

References (26)

1. Friis-Moller N, Sabin CA, Weber R, D'Arminio MA, El-Sadr WM, Reiss P, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
2. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
3. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
4. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, Gerstoft J. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625-1631.
5. El Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. Rappoport, CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
6. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 1990; 16:349-356.
7. Zeiher AM, Schachinger V, Weitzel SH, Wollschlager H, Just H. Intracoronary thrombus formation causes focal vasoconstriction of epicardial arteries in patients with coronary artery disease. Circulation 1991; 83:1519-1525.
8. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE. Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 1995; 74:247-253.
9. Beanlands RS, Muzik O, Melon P, Sutor R, Sawada S, Muller D, et al. Noninvasive quantification of regional myocardial flow reserve in patients with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. Determination of extent of altered vascular reactivity. J Am Coll Cardiol 1995; 26:1465-1475.
10. Demer LL, Gould KL, Goldstein RA, Kirkeeide RL, Mullani NA, Smalling RW, et al. Assessment of coronary artery disease severity by positron emission tomography. Comparison with quantitative arteriography in 193 patients. Circulation 1989; 79:825-835.
11. Kjaer A, Meyer C, Nielsen FS, Parving HH, Hesse B. Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: @@a PET study of myocardial perfusion in diabetes. J Nucl Med 2003; 44:19-23.
12. Kjaer A, Meyer C, Wachtell K, Olsen MH, Ibsen H, Opie L, et al. Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy. Am J Cardiol 2005; 96:1692-1698.
13. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257-265.
14. Blanco JJ, Garcia IS, Cerezo JG, De Rivera JM, Anaya PM, Raya PG, et al. Endothelial function in HIV-infected patients with low or mild cardiovascular risk. J Antimicrob Chemother 2006; 58:133-139.
15. Charakida M, Donald AE, Green H, Storry C, Clapson M, Caslake M, et al. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy. Circulation 2005; 112:103-109.
16. Dube MP, Gorski JC, Shen C. Severe impairment of endothelial function with the HIV-1 protease inhibitor indinavir is not mediated by insulin resistance in healthy subjects. Cardiovasc Toxicol 2008; 8:15-22.
17. Hsue PY, Hunt PW, Wu Y, Schnell A, Ho JE, Hatano H, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS 2009; 23:2021-2027.
18. Jiang B, Hebert VY, Zavecz JH, Dugas TR. Antiretrovirals induce direct endothelial dysfunction in vivo. J Acquir Immune Defic Syndr 2006; 42:391-395.
19. Shankar SS, Dube MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J 2005; 150:933.
20. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
21. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dube MP, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008; 52:569-576.
22. Yavuz BB, Yavuz B, Sener DD, Cankurtaran M, Halil M, Ulger Z, et al. Advanced age is associated with endothelial dysfunction in healthy elderly subjects. Gerontology 2008; 54:153-156.
23. Cooper DC, Milic MS, Tafur JR, Mills PJ, Bardwell WA, Ziegler MG, Dimsdale JE. Adverse impact of mood on flow-mediated dilation. Psychosom Med 2010; 72:122-127.
24. Kristoffersen US, Kofoed K, Kronborg G, Giger AK, Kjaer A, Lebech AM. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 2009; 10:79-87.
25. Stein JH, Komarow L, Cotter BR, Currier JS, Dube MP, Fichtenbaum CJ, et al. Lipoprotein changes in HIV-infected antiretroviral-naive individuals after starting antiretroviral therapy: ACTG Study A5152s Stein: lipoprotein changes on antiretroviral therapy. J Clin Lipidol 2008; 2:464-471.
26. Lebech AM, Kristoffersen US, Wiinberg N, Kofoed K, Andersen O, Hesse B, et al. Coronary and peripheral endothelial function in HIV patients studied with positron emission tomography and flow-mediated dilation: relation to hypercholesterolemia. Eur J Nucl Med Mol Imaging 2008; 35:2049-2058.